After adjusting for clinical features, including age, sex, tumor stage, and smoking, as well as the driver gene mutation (EGFR, KRAS, ALK, ROS1, BRAF, and TP53), the DRG served as an independent prognostic biomarker for predicting outcomes (OS, HR: 0.42 (0.30–0.58); DFS, HR: 0.43 (0.31–0.53), Table 1). Here, KRAS is linked to neoplasm.